Aviceda has assembled a renowned team of scientific entrepreneurs and biopharma senior executives to spearhead ongoing development efforts of pipeline candidates and help the company continue to explore growth opportunities.Full article
In this Healio Video Perspective from the virtual Eyecelerator conference, Derek Kunimoto, MD, JD, co-founder and chief operating officer of Aviceda Therapeutics, speaks on the company’s progress toward an effective dry AMD treatment.Full article
An internationally renowned group of scientists, researchers and clinicians will work with Aviceda’s in-house team to spearhead development of the next generation of glyco-immune therapeutics.Full article
Platform technologies are known for having the ability to significantly improve the current product and generate a completely novel product. This, in turn, leads up to the opening of new avenues for drug development and discoveries, potentially increasing the therapeutic options for patients.Full article
“Chris and Nancy will add significant value to our world-class, cross-disciplinary team and scientific advisory board and will help continue the progress we..." said Mohamed A. Genead, MD, Chairman & CEO of Aviceda Therapeutics.Full article
Aviceda Therapeutics' portfolio company, Aviceda Ophthalmics own Chief Operating Officer and Co-Founder Derek Kunimoto, was interviewed during the Annual meeting for American Society of Retina Specialists (ASRS) to share an update about Aviceda's lead optimized nanoparticle (AVD-104) for treatment patients with age-related macular degeneration (AMD).Full article
Aviceda is headquartered in Cambridge, Massachusetts with research partnership sites in San Diego, Georgia, Belfast, and Paris.